Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12
Phase 22

Trial Status

Completed4

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Clinical Trials (4)

NCT00121264Phase 1Completed
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
Unspecified Adult Solid Tumor, Protocol Specific
Principalinvestigator
NCT01468532Phase 1/2Completed
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Principalinvestigator
NCT01656304Phase 2Completed
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate Cancer+3 more
Principalinvestigator
NCT01812668Not ApplicableCompleted
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Stage IV Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate Cancer+1 more
Similarity Score13%

Jun Mao, MD, MSCE

Memorial Sloan Kettering Cancer Center

Related
13 trials

Shared therapeutic areas:

Stage I Prostate CancerStage III Prostate Cancer
Similarity Score7%

Ingrid Mayer, MD

Vanderbilt-Ingram Cancer Center

Related
13 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

Genentech, Inc.National Cancer Institute (NCI)
Similarity Score3%

Heinz-Josef Lenz, MD

University of Southern California

Related
13 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Scot C. Remick, MD

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Related
13 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Corey J. Langer, MD

Fox Chase Cancer Center

Related
16 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Gustavo Leone

Medical University of South Carolina, Hollings Cancer Center

Related
12 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

Genentech, Inc.
Similarity Score3%

Jorge Cortes, MD

M.D. Anderson Cancer Center

Related
24 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

William I. Bensinger, MD

Fred Hutchinson Cancer Center

Related
12 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Thomas E. Witzig, MD

Mayo Clinic

Related
12 trials

Shared therapeutic areas:

Unspecified Adult Solid Tumor, Protocol Specific

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT00121264Phase 1PrincipalInvestigator

17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific
Completed
NCT01468532Phase 1/2PrincipalInvestigator

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Completed
NCT01656304Phase 2PrincipalInvestigator

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

Adenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate Cancer+3 more
Completed
NCT01812668Not ApplicablePrincipalInvestigator

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Completed

All 4 trials loaded